Get started
Author

Louise Roulin

Observed names: L Roulin, L. Roulin
Observed institutions: Centre National de la Recherche Scientifique, Inserm, Université Paris-Est Créteil, Centre Hospitalier Universitaire Henri-Mondor, Génomes, biologie cellulaire et thérapeutiques, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Hospital Universitario Doctor Peset, Hôpitaux Universitaires Henri-Mondor, Hôpital Albert-Chenevier, Institut Mondor de Recherche Biomédicale, Université Paris Diderot, Institut Universitaire d'Hématologie, Laboratoire d'hématologie
ORCID: 0000-0003-4686-9273
Observed ORCID: 0000-0003-4686-9273
OpenAlex ID: A5086219277
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
2022 · Emmanuel Bachy, Steven Le Gouill, et al. · Nature Medicine · 406
PDF
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
2020 · Laetitia Vercellino, Anne-Segolene Cottereau, et al. · Blood · 186
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation
2021 · Clarisse Cazelles, Karim Belhadj, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 47
PDF
Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort
2023 · Enora Le Goff, Paul Blanc‐Durand, et al. · British Journal of Haematology · 20
PDF
Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis
2021 · Hélène Pasquer, Karim Belhadj, et al. · British Journal of Haematology · 18
Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
2019 · Catherine Thieblemont, Susannah Howlett, et al. · British Journal of Haematology · 18
PDF
Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France
2023 · Thibaud Damy, Amira Zaroui, et al. · Archives of cardiovascular diseases · 16
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
2022 · Catherine Thieblemont, Javier Munoz, et al. · Blood · 15
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
2022 · Simon B. Gressens, Slim Fourati, et al. · Clinical Microbiology and Infection · 13
PDF
A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry
2021 · Emmanuel Bachy, Steven Le Gouill, et al. · Blood · 12
Prognostic Mortality Factors in Advanced Light Chain Cardiac Amyloidosis: A Prospective Cohort Study
2024 · Amira Zaroui, Mounira Kharoubi, et al. · ESC Heart Failure · 11
Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.
2019 · Fabien Le Bras, Jehan Dupuis, et al. · Journal of Clinical Oncology · 11
Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study
2025 · Xavier Phina-Ziebin, Emmanuel Bachy, et al. · Blood Advances · 10
Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry
2022 · Hedi Bensaber, Emmanuel Bachy, et al. · Blood · 10
Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment
2020 · Romain Gounot, Fabien Le Bras, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias
2019 · Aline Massé, Louise Roulin, et al. · Leukemia Research · 9
Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry
2025 · Federico Erbella, Emmanuel Bachy, et al. · Blood Advances · 7
PDF
Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis
2022 · Hajer Abroud, Asma Beldi‐Ferchiou, et al. · eJHaem · 6
The Spectrum of Chronic CD8+ T-Cell Expansions: Clinical Features in 14 Patients
2014 · Etienne Ghrenassia, Louise Roulin, et al. · PLoS ONE · 6
PDF
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group
2025 · Marion Aymard, Morgane Cheminant, et al. · Blood Advances · 5
PDF
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas
2025 · Pierre Stephan, Roberta Di Blasi, et al. · Blood Advances · 5
PDF
High Total Metabolic Tumor Volume at Baseline Allows to Discriminate for Survival Patients in Response After R‐chop: an Ancillary Analysis of the Remarc Study
2019 · A. Cottereau, L. Vercellino, et al. · Hematological Oncology · 5
PDF
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients
2023 · Pierre Walczak, Sylvain Choquet, et al. · Haematologica · 4
PDF
Large B-cell lymphoma: The LYSA pragmatic guidelines
2025 · Pierre Sesques, Guillaume Manson, et al. · European Journal of Cancer · 3
PDF
Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry
2022 · Federico Erbella, Emmanuel Bachy, et al. · Blood · 3
Works count: 47
Citation count: 870
H-index: 11
I10-index: 14
Year
Topic
Type